This comprehensive case study explores Kymanox’s approach to microneedle patch drug delivery development through integrated Human Factors (HF) validation and packaging engineering. Our team of Subject Matter Experts (SMEs), including former FDA staff, collaborated closely with biopharmaceutical stakeholders to implement measurable improvements across formative studies, Instructions for Use (IFU) optimization, packaging design, and risk mitigation strategies for innovative transdermal delivery systems.
CHALLENGE
SOLUTION
RESULTS
- Biopharmaceutical company required HF study support for microneedle patch drug delivery system ensuring FDA approval and market readiness.
- Packaging component development needed for microneedle patch system with focus on usability and regulatory compliance.
- HF optimization essential to avoid potential FDA-mandated training requirements that could significantly delay project timelines and increase costs.
- Comprehensive strategy required integrated packaging engineering with HF validation to support successful regulatory submission.
- Engaged Kymanox HF experts, including former FDA staff, to develop comprehensive HF strategy aligned with regulatory expectations.
- Reviewed formative study results providing expert recommendations in IFU layout, wording, and diagrams ensuring alignment with intended user needs.
- Integrated quick reference guide within IFU consolidating user instructions into single document, improving usability and comprehension.
- Strengthened User Failure Modes and Effects Analysis (uFMEA) documentation with robust risk mitigation strategies meeting FDA regulatory and ISO 14971 standards.
- Deployed packaging technology and engineering experts to evaluate and develop packaging and labeling designs focusing on usability and HF integration.
- Coordinated cross-functional collaboration between HF and packaging teams supporting comprehensive validation studies.
- Successfully completed formative evaluations minimizing risk of FDA-mandated training requirements that would delay product launch.
- Supported timely project execution while mitigating budget impact by reducing potential compliance-related delays.
- Developed robust HF and packaging strategy positioning microneedle patch delivery system for FDA approval and commercial success.